抗结核药物的研究进展
作者：陈雪融;
Author：
收稿日期： 年卷（期）页码：2016,31(06):-668-670
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：抗结核药;抗结核;抗生素类;噁唑烷酮类;二芳基喹啉类;硝基咪唑类;贝塔喹啉;德拉马尼
Key words：
基金项目：国家自然科学青年基金资助项目(批准号:81202375);;
四川省科技厅国际合作项目(No.2014HH0003)
中文摘要
抗结核药物的研究近年来取得了重要进展,尤以贝塔喹啉和德拉马尼的问世成为结核化疗史的新里程碑。
参考文献
[1]中国防痨协会.耐药结核病化学治疗指南(2015)[J].中国防痨杂志,2015,37(5):421-469.
[2]World Health Organization.Companion handbook to the WHOguidelines for theprogrammatic management of drug-resistant tuberculosis[M].Geneva:World Health Organization,2014.
[3]Tandon VR,Rani N,Roshi.Cycloserine induced psychosis with hepatic dysfunction[J].Indian J Pharmacol,2015,47(2):230-241.
[4]Dey T,Brigden G,Cox H.Outcomes of Clofazimine for the treatment of drug-resistant tuberculosis:A systematic review and meta-analysis[J].J Antimicrob Chemother,2013,68(2):284-293.
[5]Padayatchi N,Gopal M,Naidoo R.Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa:A retrospective cohort study[J].J Antimicrob Chemother,2014,69(11):3103-3107.
[6]Gillespie SH,Crook AM,McH ugh TD.Four-month Moxifloxacin-based regimens for drug-sensitive tuberculosis[J].N Engl J Med,2014,371(17):1577-1587.
[7]Lee M,Lee J,Carroll MW.Linezolid for treatment of chronic extensively drug-resistant tuberculosis[J].N Engl J Med,2012,367(16):1508-1518.
[8]Carroll MW,Choi H,Min S.Rhabdomyolysis in a patient treated with Linezolid for extensively drug-resistant tuberculosis[J].Clin Infect Dis,2012,54(11):1624-1627.
[9]卢曦,杨信怡,游雪甫.抗结核药物最新研究进展[J].药学研究,2013,32(1):36-41
[10]Manika K,Giouleka P,Zarogoulidis K.Multidrug-resistant tuberculosis in an adult with cystic fibrosis[J].Respiration,2013,85(4):350-353.
[11]Diacon AH,Pym A,Grobusch M.The diarylquinoline TMC207 for multidrug-resistant tuberculosis[J].N Engl J Med,2009,360(23):2397-2405.
[12]Diacon AH,Pym A,Grobusch MP.Multidrug-resistant tuberculosis and culture conversion with bedaquiline[J].N Engl J Med,2014,371(8):723-732.
[13]Guglielmetti L,Le DD,Jachym M.Compassionate use of Bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis:Interim analysis of a French cohort[J].Clin Infect Dis,2015,60(2):188-94.
[14]Pontali E,Sotgiu G,D'Ambrosio L.Bedaquiline and multidrugresistant tuberculosis:A systematic and critical analysis of the evidence[J].Eur Respir J,2016,47(2):394-402.
[15]Bloemberg GV,Keller PM,Stucki D.Acquired resistance to Bedaquiline and Delamanid in therapy for Tuberculosis[J].N Engl JMed,2015,373(20):1986-1988.
[16]Lewis JM,Sloan DJ.The role of Delamanid in the treatment of drug-resistant tuberculosis[J].Ther Clin Risk Manag,2015,11(5):779-791
[17]Skripconoka V,Danilovits M,Pehme L.Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis[J].Eur Respir J,2013,41(6):1393-1400.
[18]夏露,卢水华.WHO德拉马尼治疗耐多药结核临时政策指导解读[C].全国结核病学术大会论文汇编,2015:81-86
[19]Reddy VM,Einck L,Andries K,et al.In vitro interactions between new antitubercular drug candidates SQ109 and TMC207[J].Antimicrob Agents Chemother,2010,54(7):2840-2846.
[20]石文卉,初乃惠.抗结核药物的应用与研发[J].中国防痨杂志,2015,37(11):1156-1159.
[21]李亮,刘宇红,杜建.结核病诊疗进展年度回眸(2015年)[J].中华结核呼吸杂志,2016,39(1):5-7.
【关闭】
